Original news and analysis on international IP policy
The World Health Organization has issued updated information on the patent status of hepatitis C medicines, including assessments of hurdles for affordable generic versions of latest drugs.
DURBAN, South Africa - The lessons derived from the history of AIDS treatment have become a rallying call for civil society organisations globally. Not being able to afford AIDS medicines should not be repeated for people with other diseases, including HIV co-infections, treatment activists told world leaders here.
NAIROBI, Kenya (IP-Watch) -- A global database on non-tariff measures (NTMs) has been launched here at the 14th United Nations Conference on Trade and Development (UNCTAD 14). Also this week the World Investment Forum kicked off, the first such event since agreement of the UN Sustainable Development Goals.
Despite "remarkable" progress by some countries on addressing noncommunicable diseases like cancer and diabetes, there is a need to accelerate efforts in order to meet agreed global commitments, the World Health Organization said this week.
A new publication analysing the relationship between intellectual property and access to science explores ways countries have developed to counter the potential barriers created by IP rights, and says patenting by universities is counterproductive.
The European Union Intellectual Property Office (EUIPO) and the European Commission Trade Directorate recently launched a new intellectual property enforcement tool that aims to pool together all data relating to IP rights infringement experienced by EU companies into one database to help build prevention strategies. This is one of many new EU initiatives to counter growing IPR infringement and counterfeits.
NAIROBI, Kenya (IP-Watch) – The United Nations Conference on Trade and Development (UNCTAD) 14th Session opened here yesterday, with leaders calling for deeper and broader cooperation between trade and development.
A new report launched in time for this week's AIDS conference in South Africa analyzes factors relating to access to HIV/AIDS treatments over the past 15 years. The analysis includes a look at government policies used during that time, the contribution of generic and research-based industries, and the importance of voluntary licensing.
Top negotiators of the European Union and United States today underlined after the 14th round of negotiations for the Transatlantic Trade and Investment Partnership (TTIP) that they are still on track for finalising the deal during the outgoing Obama administration. At the same time, they acknowledged that after three years of negotiations some chapters have never been discussed.
Worldwide sales for orphan drugs are forecast to reach $178 billion by 2020, according to a recent industry report. Moreover, the orphan drug market is expected to grow almost 12 percent per year, a level the broader pharmaceutical market “could only dream about” with its expected annual growth of 5.9 percent, according to Lisa Urquhart, editor of EvaluatePharma Vantage.
Days before a major meeting of the governing body of the United Nations Conference on Trade and Development (UNCTAD), over 100 non-governmental organisations worldwide are calling for the organisation to maintain its development role and not help implement international and regional trade rules.
Gilead is the US company whose use of patents to charge $1000 per pill for a hepatitis C medicine in the United States helped make high drug prices a developed country household issue and fodder for elected officials seeking change. Now the company has come under further fire after being found to have moved some US$10 billion overseas to avoid US taxes - even after having received US taxpayer support for its activities - which it orchestrated by moving its patent rights overseas. A new report detailing the company's tax dodge includes a proposal for a way to clamp down on this type of patent activity.